Results 91 to 100 of about 93,929 (247)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Focal adhesion kinase: Insight into molecular roles and functions in hepatocellular carcinoma [PDF]

, 2017
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Due to the high incidence of post-operative recurrence after current treatments, the identification of new and more effective drugs is required.
Alisi, Anna, Crudele, Annalisa, Gnani, Daniela, Panera, Nadia, Romito, Ilaria   +4 more
core   +2 more sources

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]

, 2016
ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni, Borbath, Ivan, Daniele, Bruno, De Toni, Enrico N, Gasbarrini, Antonio, Lamar, Maria E, Lencioni, Monica, Miles, Steven, Personeni, Nicola, Porta, Camillo, Rimassa, Lorenza, Salvagni, Stefania, Santoro, Armando, Schwartz, Brian E, Shuster, Dale, Trojan, Jörg, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Wang, Yunxia, Weiss, Alan   +19 more
core   +4 more sources

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

Health Care Science, EarlyView.
Findings indicate that within a standardized clinical pathway integrating structured immunosuppression, therapeutic drug monitoring, and early complication surveillance, liver transplantation after ICI exposure can be performed safely without increased rejection risk.
Ning Wang, Zebin Zhu, Hao Zheng, Can Qi, Xiaodong Yuan, Xuefeng Li, Zhijun Xu, Jiwei Qin, Wei Wu, Jizhou Wang, Ruipeng Song, Zhiyong Guo, Lianxin Liu, Shu‐Geng Zhang, Björn Nashan   +14 more
wiley   +1 more source

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

Cancer Medicine, 2020
Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker.
Pusen Wang, Zhongyi Jiang, Xueni Liu, Kanru Yu, Chunguang Wang, Hao Li, Lin Zhong   +6 more
doaj   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core  

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L., Conner, J., Graham, A., Graham, S.V.   +3 more
core   +1 more source

RETRACTED ARTICLE: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Cancer Cell International, 2019
Background Effective therapy for hepatocellular carcinoma (HCC) is currently an imperative issue, and sorafenib is a first-line drug for the treatment of HCC. However, the clinical benefit of sorafenib is often impaired by drug resistance.
Jie Song, Wei Zhao, Chang Lu, Xue Shao
doaj   +1 more source

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. [PDF]

, 2017
BackgroundInternal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival.
Altman, Jessica K, Baer, Maria R, Bahceci, Erkut, Claxton, David, Cortes, Jorge, Erba, Harry P, Gill, Stan, Goldberg, Stuart, Jurcic, Joseph G, Larson, Richard A, Levis, Mark, Litzow, Mark, Liu, Chaofeng, Martinelli, Giovanni, Neubauer, Andreas, Perl, Alexander E, Ritchie, Ellen, Röllig, Christoph, Schiller, Gary, Smith, Catherine, Spira, Alexander I, Strickland, Stephen A, Stuart, Robert, Tibes, Raoul, Ustun, Celalettin, Wang, Eunice S   +25 more
core   +1 more source